Tumour-specific animal proteins
AssigneeGlaxosmithkline Biologicals SA
InventorsTeresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
Life of this patent
Estimating the term…
Abstract
CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.
Claims9
An isolated peptide consisting of a 9-15 amino acid fragment of SEQ ID NO:2, wherein said fragment encompasses an epitope;
- wherein said epitope consists of an amino acid sequence selected from SEQ ID NOs:16-33, and
- wherein said peptide binds to polyclonal antibodies against CASB7439 having SEQ ID NO:2.
An isolated peptide consisting of a 9-10 amino acid fragment of SEQ ID NO:2, wherein said fragment encompasses an epitope;
- wherein said epitope consists of an amino acid sequence selected from SEQ ID NOs:16-33, and
- wherein said peptide binds to polyclonal antibodies against CASB7439 having SEQ ID NO:2.
An isolated peptide consisting of a 9-15 amino acid fragment of SEQ ID NO:2, wherein said fragment encompasses an amino acid sequence selected from SEQ ID NOs:16-33, and wherein said peptide binds to polyclonal antibodies against CASB7439 having SEQ ID NO:2.
Dependencies are inferred from the claim text.